Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Equities researchers at Wedbush raised their Q1 2025 EPS estimates for Fate Therapeutics in a research note issued to investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.42) per share for the quarter, up from their previous estimate of ($0.49). Wedbush has a "Neutral" rating and a $5.00 price objective on the stock. The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share. Wedbush also issued estimates for Fate Therapeutics' Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($1.30) EPS and FY2028 earnings at ($1.84) EPS.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $1.57 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%.
A number of other research analysts also recently weighed in on FATE. StockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday. Stifel Nicolaus dropped their price objective on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. Bank of America raised shares of Fate Therapeutics from an "underperform" rating to a "neutral" rating in a research note on Monday, November 18th. Finally, Wells Fargo & Company dropped their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $5.50.
View Our Latest Research Report on Fate Therapeutics
Fate Therapeutics Stock Performance
Shares of FATE traded down $0.05 during trading hours on Monday, hitting $0.96. The stock had a trading volume of 1,849,561 shares, compared to its average volume of 2,523,478. The firm has a market capitalization of $109.78 million, a price-to-earnings ratio of -0.57 and a beta of 2.26. The firm has a 50-day moving average price of $1.32 and a 200 day moving average price of $2.30. Fate Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $7.70.
Insiders Place Their Bets
In other Fate Therapeutics news, Director Redmile Group, Llc bought 397,964 shares of Fate Therapeutics stock in a transaction on Friday, December 20th. The shares were bought at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the completion of the transaction, the director now directly owns 12,884,277 shares of the company's stock, valued at $21,645,585.36. This trade represents a 3.19 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 5.00% of the stock is owned by insiders.
Institutional Trading of Fate Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of FATE. Vestal Point Capital LP increased its position in shares of Fate Therapeutics by 46.3% during the fourth quarter. Vestal Point Capital LP now owns 2,465,000 shares of the biopharmaceutical company's stock valued at $4,067,000 after acquiring an additional 780,000 shares during the last quarter. Squarepoint Ops LLC boosted its position in shares of Fate Therapeutics by 154.2% during the 4th quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 20,805 shares during the period. Tang Capital Management LLC increased its holdings in Fate Therapeutics by 165.1% in the 4th quarter. Tang Capital Management LLC now owns 1,855,954 shares of the biopharmaceutical company's stock valued at $3,062,000 after purchasing an additional 1,155,954 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in Fate Therapeutics in the 4th quarter valued at approximately $655,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Fate Therapeutics in the fourth quarter valued at approximately $55,000. 97.54% of the stock is currently owned by hedge funds and other institutional investors.
Fate Therapeutics Company Profile
(
Get Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Stories
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
